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Monitoring clinical progression with
mitochondrial disease biomarkers
Hannah E. Steele,1 Rita Horvath,1 Jon J. Lyon2 and Patrick F. Chinnery3,4
Mitochondrial disorders are genetically determined metabolic diseases due to a biochemical deficiency of the respiratory chain.
Given that multi-system involvement and disease progression are common features of mitochondrial disorders they carry substan-
tial morbidity and mortality. Despite this, no disease-modifying treatments exist with clear clinical benefits, and the current best
management of mitochondrial disease is supportive. Several therapeutic strategies for mitochondrial disorders are now at a mature
preclinical stage. Some are making the transition into early-phase patient trials, but the lack of validated biomarkers of disease
progression presents a challenge when developing new therapies for patients. This update discusses current biomarkers of mito-
chondrial disease progression including metabolomics, circulating serum markers, exercise physiology, and both structural and
functional imaging. We discuss the advantages and disadvantages of each approach, and consider emerging techniques with a
potential role in trials of new therapies.
1 Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne,
NE1 3BZ, UK
2 GlaxoSmithKline, Molecular Safety and Disposition, Ware, SG12 0DP, UK
3 Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
4 MRC Mitochondrial Biology Unit, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
Correspondence to: Patrick F Chinnery
Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
E-mail: pfc25@cam.ac.uk
Keywords: biomarkers; mitochondrial disease; disease progression; mtDNA; mitochondrial encephalomyopathy
Abbreviations: MELAS = mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes; MRS = magnetic resonance
spectroscopy; NMR = nuclear magnetic resonance; OEF = oxygen extraction fraction
Introduction
Mitochondrial disorders are genetically determined meta-
bolic diseases due to a biochemical deficiency of the respira-
tory chain that affect around 1 in 4300 of the population
in the UK (Gorman et al., 2015). Given that multisystem
involvement and disease progression are common features,
mitochondrial disorders carry substantial morbidity and are
associated with excess premature death (Kaufmann et al.,
2011). Despite this burden, a recently published Cochrane
review did not identify any disease-modifying treatments of
benefit (Pfeffer et al., 2012), and current best management
of mitochondrial disease is therefore supportive.
Consequently there is an unmet need for treatments that
modify the underlying biochemical deficit and disease
trajectory.
However, the development of new therapeutic strategies
presents major challenges for the scientific, pharmaceutical,
academic and clinical communities (Food and Drug
Administration, 2004). For rare diseases, including mito-
chondrial disorders, these issues are magnified through
the geographical dispersion of patients, the use of
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heterogeneous patient groups in both interventional and
natural history studies to date, and historically at least, a
perceived lack of return on financial investment for the
pharmaceutical industry (Pfeffer et al., 2013). As biomarker
identification provides a means of overcoming some of
these barriers—for example, enabling prospective com-
pounds to be assessed in a practical timescale, or facilitat-
ing patient subgroup categorization—their development has
been afforded high scientific priority (Food and Drug
Administration, 2004).
Biomarkers are widely defined as: ‘A characteristic that is
objectively measured and evaluated as an indicator of
normal biologic processes, pathogenic processes, or
pharmacologic response(s) to a therapeutic intervention’
(Biomarkers Definitions Working Group, 2001). With
increasing scientific focus on developing biomarkers, an ex-
pansive nomenclature has emerged (Biomarkers Definitions
Working Group, 2001; Altar et al., 2008; Wagner, 2008).
‘Drug-related’ biomarkers are those identifying novel path-
ways, or enabling assessment of drug-target interactions;
while ‘disease-related’ biomarkers reflect the presence or
absence of disease, aid disease stratification, guide progno-
sis or inform disease natural history (Fig. 1). Following
identification of a potential biomarker, it should be both
validated and qualified: where validation refers to the pro-
cess of determining assay reliability, and qualification de-
scribes the process of linking a biomarker with biological
processes and clinical endpoints. Where biomarkers have a
specific purpose, in a specific patient cohort, their impact
on clinical trial design is outlined in Fig. 1.
Traditionally, biomarkers in mitochondrial diseases have
been used to improve diagnostic accuracy or target those
who should undergo invasive investigation. However, as
next generation sequencing techniques progressively im-
prove the diagnostic process (Taylor et al., 2014), alterna-
tive uses of biomarkers can be increasingly explored. As
several therapeutic strategies for mitochondrial disorders
are now at a mature preclinical stage (Bogacka et al.,
2005; Lagouge et al., 2006; Yatsuga and Suomalainen,
2012), and are making the transition into early-phase pa-
tient trials (Table 1), it is the lack of validated biomarkers
for disease progression that currently presents the biggest
challenge in developing new therapies for patients.
The unmet need for surrogate markers of disease pro-
gression becomes clear when considering three key clinical
features of mitochondrial diseases. First, the disorders are
notoriously heterogeneous—even within genetically homo-
geneous groups. Second, acute relapses are frequently
experienced; and third, baseline progression tends to
occur slowly over a number of years. In the context of
clinical trials, and particularly early phase trials that tend
to be conducted over short timescales (e.g. 6 weeks to 6
months), these factors present significant barriers in deter-
mining therapeutic efficacy. Given this, our review will
focus on scientific approaches to identify biomarkers of
clinical disease progression in mitochondrial disorders
with a unique emphasis on emerging preclinical tech-
niques. We are aware that mitochondrial abnormalities
may be secondary to various cellular processes including
calcium metabolism, neurode generation and various meta-
bolic diseases; however, the role of mitochondria in these
diseases needs further investigations (Pyle et al., 2015).
Therefore, we focus this update on primary mitochondrial
disorders.
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Figure 1 Potential impact of biomarkers on clinical trials.
Biomarkers for mitochondrial disease BRAIN 2017: 140; 2530–2540 | 2531
Metabolomics
A fundamental feature of primary mitochondrial disorders
is deficient oxidative phosphorylation, with both up- and
downstream metabolic perturbations arising secondarily.
Abnormalities in lactate, pyruvate, creatine kinase, amino
acids and carnitines are firmly established in the clinical
investigation of mitochondrial diseases. However, their
diagnostic sensitivity and specificity is poor (Petty et al.,
1986; Campos et al., 1993; Jackson et al., 1995; Sim
et al., 2002; Jeppesen et al., 2006a; Haas et al., 2008;
Suomalainen et al., 2011; Yamada et al., 2012; Davis
et al., 2013) and there are limited natural history studies
studying change in relation to disease progression. To date,
metabolomic approaches have been highly successful in
identifying potential biomarkers in a diverse range of dis-
orders including: cancers (Puchades-Carrasco et al., 2013;
Rocha et al., 2015; Cui et al., 2016), vascular disease (Jove
et al., 2015; Naz et al., 2015), renal transplantation
(Kienana et al., 2015), respiratory diseases (Adamko
et al., 2015), immunological disorders (Young et al.,
2013; Saegusa et al., 2014), liver disease (Gao et al.,
2015), and diabetes (Balderas et al., 2013; Drogan et al.,
2015). With secondary mitochondrial dysfunction arising
in several of these conditions (Wallace, 2012; Yu et al.,
2012; Begriche et al., 2013; Cloonan and Choi, 2016),
alongside the association of diabetes with primary mito-
chondrial diseases, the application of metabolomics in gen-
etically determined mitochondrial cohorts is timely and
holds great potential.
For a multi-systemic disorder, a particularly attractive
feature of metabolomic analysis is that it can be undertaken
using CSF, blood, urine, saliva, or solid biopsy samples. It
is unknown at present which of these is optimal in mito-
chondrial disorders specifically, but non-invasive (urine/
saliva) or minimally invasive (blood) samples would facili-
tate repeated measurements in both longitudinal and thera-
peutic settings. Initial study of the urinary proteome and
metabolome in patients with heterogeneous mitochondrial
disorders identified key differences between carriers,
healthy controls and those manifesting symptoms (Hall
et al., 2015).
Analysis can be undertaken using either nuclear magnetic
resonance spectrometry (NMR spectrometry) or mass spec-
trometry (MS) techniques. NMR spectrometry can utilize
samples in both solid and liquid states; is highly reprodu-
cible, and is better at analyte quantification than mass spec-
trometry (Emwas, 2015). However, mass spectrometry
techniques have significantly higher sensitivity than NMR
spectrometry, enabling detection of analytes at low concen-
trations (femto–attomolar) thereby facilitating recognition
of metabolites not traditionally measured in routine clinical
practice, with a relevant example being the alteration of
sphingomyelins and phosphatidylcholines in a cohort with
Leber’s hereditary optic neuropathy (Chao de la Barca
et al., 2016).
Furthermore, data arising from metabolomics studies can
be used in a variety of clinically meaningful ways. In add-
ition to genotype or phenotype specific cohort analysis
identifying specific disease manifesting and carrier
Table 1 Active clinical trials of potential disease modifying agents for primary mitochondrial diseases,
ClinicalTrials.gov April 2017
Study title Phase Design IMP
The effect of arginine and citrulline supplementation on endothelial dysfunction in
mitochondrial diseases
II R, PC, DB, CO Arginine, citrulline
Study to assess the efficacy and safety of Raxone in LHON patients (LEROS) IV OL Idebenone
An exploratory, double-blind, randomized, placebo-controlled, single-center, two-way
cross-over study with KH176 in patients with the mitochondrial DNA
tRNALeu(UUR) m.3243A4G mutation and clinical signs of mitochondrial disease
II R, PC, DB, CO KH173
A study of bezafibrate in mitochondrial myopathy II OL Bezafibrate
RTA 408 capsules in patients with mitochondrial myopathy - MOTOR II R, PC, DB RTA408
Efficacy study of GS010 for the treatment of vision loss up to 6 months from
onset in LHON due to the ND4 mutation (RESCUE)
III R, Sham C, DB GS010
EPI-743 for metabolism or mitochondrial disorders II R, PC, DB, CO EPI-743
MNGIE allogeneic hematopoietic stem cell transplant safety study (MASS) I OL Hematopoietic
allogeneic
stem cells
A study investigating the safety, tolerability, and efficacy of elamipretide (MTP-131)
topical ophthalmic solution for the treatment of Leber’s hereditary optic
neuropathy
II R, PC, DB MTP-131
Safety study of an adeno-associated virus vector for gene therapy of Leber’s hereditary
optic neuropathy (LHON) caused by the G11778A mutation (LHON GTT)
I OL scAAV2-P1ND4v2
Long term safety and efficacy study of EPI-743 in children with Leigh syndrome II R, PC, DB EPI-743
CO = crossover; DB = double blinded; IMP = investigational medicinal product; OL = open label; PC = placebo controlled; R = randomized; Sham C = sham controlled.
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‘signatures’ (Hall et al., 2015), longitudinal ‘n-of-1’ studies
can be undertaken to facilitate analysis of metabolomic
change with an individual’s clinical disease progression
(Alonso et al., 2015). The ability to combine these
approaches is particularly attractive and could help with
the presymptomatic identification of ‘disease onset’ in car-
rier individuals—a factor of clear importance for clinical
trial design.
Circulating serum markers
Circulating cytokines
In the past 5 years, serum fibroblast growth factor-21
(FGF-21) and serum growth and differentiation factor-15
(GDF-15) (Kajiyama et al., 1989; Suomalainen et al., 2011;
Davis et al., 2013; Kalko et al., 2014; Fujita et al., 2015;
Yatsuga et al., 2015) have emerged as two promising diag-
nostic biomarkers for mitochondrial diseases. Identified first
in mouse models of mitochondrial disease they were subse-
quently validated in patient cohorts. Presently, both mar-
kers are more sensitive and specific than currently used
clinical diagnostic markers of mitochondrial disorders but
are yet to be incorporated into formal diagnostic pathways
(Suomalainen et al., 2011; Yatsuga et al., 2015; Davis
et al., 2016). In part, this has been due to concerns that
both have been associated with a range of non-mitochon-
drial disorders, encompassing obesity, cancer, renal disease,
diabetes, and liver disease, with the latter two frequently
co-existing in patients with mitochondrial disorders (Semba
et al., 2012; Chow et al., 2013).
Although preliminary data suggested that FGF-21 may
correlate with disease severity and disease progression
(Suomalainen et al., 2011), this was not subsequently sub-
stantiated in adult cohorts with the m.3243A4G mutation
(Koene et al., 2014, 2015). Their utility in determining dis-
ease progression and severity therefore needs further assess-
ment in broader, well characterized mitochondrial cohorts.
Additionally, it is not known whether they are influenced
by therapeutic agents, but both markers should be con-
sidered for inclusion as study endpoints in relevant clinical
trials, particularly as emerging work suggests that GDF-15,
and FGF-21 in particular, appear to be more specific mar-
kers for mitochondrial disorders arising due to mitochon-
drial translation and mtDNA maintenance defects, as
opposed to those resulting from impaired respiratory
chain complex or assembly factors (Lehtonen et al., 2016).
MicroRNAs
MicroRNAs are non-coding genomic regions, around 20
nucleotides long, that control gene expression through tran-
scription silencing. Several studies have used serum
microRNAs in the diagnosis of inherited muscle disease
(Cacchiarelli et al., 2011; Endo et al., 2013; Hu et al.,
2014), and serum circulating, muscle-specific microRNAs
have been linked to disease progression in myotonic dys-
trophy (Koutsoulidou et al., 2015). Distinctive microRNA
patterns have also been associated with various metabolic
processes including non-alcoholic fatty liver disease (Leti
et al., 2015), diabetes (Raffort et al., 2015), brown adipo-
genesis (Zhang et al., 2015), as well as exercise capacity in
healthy individuals (Mooren et al., 2014). Their interaction
with the mitochondrial genome has not been fully eluci-
dated but a recent study in cybrid cells carrying the
m.3243A4G mutation identified that microRNA-9/9* pat-
terns associated with mitochondrial disorder phenotypes
[mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes (MELAS) and myoclonic epilepsy
with ragged-red fibres (MERRF)] (Meseguer et al., 2015).
Given that serum samples are straightforward to collect,
further study of microRNAs in relation to mitochondrial
disease phenotype and disease progression would be rap-
idly feasible.
Exercise physiology
The functional assessment of mitochondrial aerobic cap-
acity in the adult patient population has been extensively
studied using exercise physiology for over 10 years. Key
differences are seen in peak oxygen consumption (peak
VO2), peak power (Wmax), and peak arterial-venous
oxygen difference between individuals with mitochondrial
disorders and healthy controls (Jeppesen et al., 2003,
2006b; Bates et al., 2013). As an indicator of oxygen
uptake from the capillary network during circulation, the
reduced peak arterial-venous oxygen difference seen in
those with mitochondrial disorders is believed to be a key
mechanism underpinning the widespread experience of ex-
ercise intolerance (Jeppesen et al., 2006b; Bates et al.,
2013).
To date, exercise testing has been used both to support a
diagnosis of mitochondrial disease (Jensen et al., 2002) and
to demonstrate efficacy of treatment (Drinkard et al., 2010;
Glover et al., 2010), including when exercise is used as a
therapy itself (Taivassalo et al., 1998, 2001, 2006; Jeppesen
et al., 2006a, b, 2009; Murphy et al., 2008; Bates et al.,
2013). To our knowledge, no longitudinal studies using
exercise physiology parameters as markers of disease pro-
gression have been undertaken in a mitochondrial cohort to
date. While exercise testing is safe in mitochondrial popu-
lations, there are several potential limitations with its use in
this way. First, studies have largely focused on those with
myopathic symptoms and application to other mitochon-
drial phenotypes is likely to require further exploration.
Second, little is published on the exercise capacity of chil-
dren with mitochondrial disorders, although a small study
reviewing exercise as a therapeutic intervention did not
identify problems with the exercise itself (Schreuder et al.,
2010). Third, participants with cardiac involvement and
significant intellectual or physical disabilities would be
unable to exercise at the level required for a valid test.
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Finally, the test requires specialist equipment and trained
staff to administer which could limit its widespread use and
reliability in longitudinal settings.
In addition to maximal exercise testing, recent work on
gait physiology has identified distinct abnormalities in the
m.3243A4G and m.8344A4G mitochondrial popula-
tions (Galna et al., 2014). These characteristics correlate
with disease severity and furthermore, affected individuals
can be distinguished from healthy controls at an early dis-
ease stage.
Imaging
Imaging findings are being increasingly identified in a broad
range of neuromuscular disorders, including as markers of
disease progression (Morrow et al., 2013, 2016). The main
focus is on the measurement of muscle volume, and the
relative amount of intramuscular fat and water (reviewed
in Carlier et al., 2016). The majority of studies to date have
been carried out in patients with inherited muscular dystro-
phies and inflammatory myopathies, but similar features
have also been shown in mitochondrial diseases, suggesting
potential applications for the diagnosis and monitoring of
these disorders. However, large longitudinal studies have
not been performed to date. The array of imaging available
to study the impact of mitochondrial disorders encom-
passes structural imaging using CT or magnetic resonance,
to functional imaging using magnetic resonance spectros-
copy (MRS) and PET. All modalities are established in
diagnostic and research settings and provide non-invasive,
quantitative measurements in a variety of tissues, making it
attractive to patients and researchers alike, particularly as
stronger magnetic fields (7 T) and novel software algo-
rithms enable shorter scan times.
Structural imaging
Structural brain imaging using MRI is well described in
mitochondrial disorders. While common clinical features
include cerebral and cerebellar atrophy, bilateral high
signal in deep grey structures, leukoencephalopathy and
stroke-like episodes in non-vascular territories (reviewed
in Saneto et al., 2008); these findings are non-specific and
highly variable (Tzoulis et al., 2006; Engelsen et al., 2008),
making them unsuitable for further development as bio-
markers. In contrast, extra-ocular muscle T2 signal in indi-
viduals with chronic progressive external ophthalmoplegia
(CPEO) correlates with eye movement restriction thereby
providing a quantitative method of assessing disease sever-
ity (Yu-Wai-Man et al., 2013; Pitceathly et al., 2016).
Similarly, in a cohort with the m.3243A4G mutation,
structural cardiac abnormalities have been identified in
the absence of both high symptom load and cardiac abnor-
mality on routine clinical tests (Hollingsworth et al., 2012).
Furthermore, the specific pattern of cardiac involvement
appears dependent on patient genotype and is distinct
from more common causes of cardiac impairment
(Florian et al., 2015). Longitudinal studies using these mod-
alities would be relatively straightforward, and both would
be potentially attractive as trial endpoints in appropriate
cohorts.
Functional imaging with existing
techniques
Magnetic resonance spectroscopy
MRS enables the quantitative assessment of tissue metab-
olites in steady state, with 31P and 1H spectra most com-
monly used in mitochondrial cohorts. 1H enables capture
of tissue-specific metabolites such as lactate, choline, and
N-acetyl aspartate, while 31P captures the relative propor-
tions of phosphorus metabolites. Although skeletal muscle
can be examined by 31P-MRS in resting, exertional or post-
exertional states, the evaluation of oxidative capacity de-
pends on measuring the phosphocreatine recovery time—a
direct reflection of mitochondrial ATP production—follow-
ing phosphocreatine depletion through exercise.
31P-MRS on skeletal muscle has identified key differences
in tissue bioenergetics in a range of neuromuscular dis-
orders, including mitochondrial disease (Lodi et al., 1999,
2004b; Cea et al., 2002; Jeppesen et al., 2007). To date
these metabolic alterations have been used to support a
diagnosis of mitochondrial disease (Walker et al., 1996;
Bernier et al., 2002) and as an endpoint in several thera-
peutic studies (Penn et al., 1992; Barbiroli et al., 1995,
1997; Kornblum et al., 2005). However, some involved
single patients only (Penn et al., 1992; Barbiroli et al.,
1995) while in others, trial design was not optimal
(Pfeffer et al., 2012). Similar abnormalities of tissue bio-
energetics have also been identified using 31P-MRS of car-
diac muscle in those carrying the m.3243A4G mutation
(Lodi et al., 2004a), and have been used to assess the ef-
fectiveness of an exercise intervention programme (Bates
et al., 2013). Longitudinal studies correlating clinical dis-
ease progression in mitochondrial cohorts with findings
from 31P-MRS studies are notably lacking.
While impaired ATP production and elevated lactate
levels are established findings of brain MRS studies
(Barbiroli et al., 1993; Kaufmann et al., 2004; Lindroos
et al., 2009), little has been published on the use of brain
MRS to monitor disease progression or to study the effects
of pharmaceutical agents (Barbiroli et al., 1999; Lee et al.,
2010). Recent work using 1H-MRS brain imaging has iden-
tified fundamental differences between healthy controls,
those manifesting disease due to the m.3243A4G muta-
tion, presymptomatic individuals converting to affected in-
dividuals and presymptomatic individuals not converting
(Weiduschat et al., 2014); once more supporting the
notion of specific disease state ‘signatures’ (Hall et al.,
2015). Natural history studies to further understand this
in relation to both symptom progression and in broader
mitochondrial patient populations would be timely and
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highly relevant given current interest in biomarker
development.
Positron emission tomography
In contrast to MRS, which provides steady state measure-
ment of metabolites, PET measures metabolic flux, thereby
permitting the study of tissue metabolic and haemodynamic
properties. Several radioisotopically labelled metabolites are
relevant to the study of mitochondrial disorders and in-
clude 15O, 2-deoxy-2 18F-fluoro-D-glucose (FDG) and 11C
pyruvate enabling the study of tissue-specific bioenergetics.
To date, PET has identified a variety of metabolic abnorm-
alities in the mitochondrial disease population. MELAS pa-
tients with the m.3243A4G point mutation are the best
studied population, with reports of PET imaging of heart
(Arakawa et al., 2010), brain (Nariai et al., 2001; Shelly
et al., 2007; Lindroos et al., 2009) and muscle tissue
(Arakawa et al., 2010; Rodan et al., 2015), both in back-
ground states (Lindroos et al., 2009), acute post stroke-like
episodes (Shelly et al., 2007; Ikawa et al., 2009), and in
response to potential therapies (Arakawa et al., 2010). Key
findings from cerebral studies include: global impairment of
cerebral oxygen metabolic rate (CMRO2) (Nariai et al.,
2001; Lindroos et al., 2009) and regional glucose hypome-
tabolism of the occipito-parietal regions (Nariai et al.,
2001; Shelly et al., 2007). These perturbations are sup-
ported by findings from heterogeneous mitochondrial
populations, which include reduced molar ratio (of glucose
and oxygen) (Frackowiak et al., 1988); impairment of
CMRO2 (Frackowiak et al., 1988; Shishido et al., 1996);
and reduced cerebral metabolic ratio glucose (CMRglu)
(Frackowiak et al., 1988; Haginoya et al., 2016), including
in a family with mitochondrial neurogastrointestinal en-
cephalopathy (MNGIE) with no clinically overt CNS fea-
tures (Lehnhardt et al., 2008). Additionally, perturbations
in cerebral oxygen extraction fraction (OEF) have been
identified, with the OEF representing the percentage of
oxygen removed from the blood by tissue during the pas-
sage through the capillary network (Frackowiak et al.,
1988; Lindroos et al., 2009). It is therefore analogous to
the ‘arterial-venous oxygen difference’ measured during
sub-maximal exercise testing, although no studies exist
that examine the relationship between the two. Further
study could therefore be warranted although PET scanning
has several limitations impeding its widespread use in both
clinical and research settings. In particular, due to the use
of radioactive isotopes (Duncan et al., 1995), there are no
natural history studies of mitochondrial populations, and
restricted studies in children with mitochondrial disorders.
Functional MRI
These limitations have provided impetus to develop magnetic
resonance protocols that facilitate study of tissue haemo-
dynamics. MRI using gradient echo sampling of spin echo
(GESSE) sequences has emerged as a technique enabling
quantitative assessments of cerebral haemodynamics, in par-
ticular the OEF (He and Yablonskiy, 2007). Key advantages
of OEF measurement over cerebral blood flow, are its rela-
tive uniformity despite regional variations in cerebral blood
flow or oxygen metabolic rate (Gusnard et al., 2001) and its
interindividual stability (He and Yablonskiy, 2007). Initial
application in a small MELAS (m.3243A4G) cohort
demonstrated reduced cerebral OEF irrespective of relation-
ship to stroke-like episode, with further reduction in OEF in
the acute and subacute phases of the stroke-like episode (Yu
et al., 2013).
Similar techniques to enable measurement of skeletal
muscle OEF have already been applied in small cohorts
of healthy individuals (Zheng et al., 2014; Wang et al.,
2016) and future assessment in patients with mitochondrial
disorders would be relevant given the reduction in tissue
oxygen extraction (peak arterial-venous oxygen difference)
widely identified during sub-maximal exercise tests in
these cohorts (Taivassalo et al., 2006). Should the muscle
OEF technique be further assessed and validated, it could
have advantage over submaximal exercise testing in a mito-
chondrial cohort because of its application to those unable
to exercise, for example, those with significant weakness,
cardiovascular disease, children or intellectual disabilities.
Functional imaging with novel
techniques
With conventional FDG-PET and NMR spectroscopy both
lacking the necessary sensitivity to identify substrates in
low tissue concentrations, researchers have developed a
relatively new MRI technique—dynamic nuclear polariza-
tion (DNP). DNP facilitates real time functional imaging,
using 13C-MRS, of substrates and their metabolites in ex-
istence at low tissue concentrations—such as reactive
oxygen species—in vivo (Ardenkjaer-Larsen et al., 2003).
Although hyperpolarized [1-13C] pyruvate has been the
most widely studied substrate, enabling both functional
imaging of key tumour metabolites (Brindle et al., 2011;
Nelson et al., 2013) and cellular response to chemotherapy
(Day et al., 2007; Ward et al., 2010), use of hyperpolarized
[1-13C] glucose permits more direct study of the glycolytic
pathway.
To date, a key limitation in the technique has been the
short half-life of the hyperpolarization period (10–40 s for
pyruvate; 51 s for glucose), necessitating the ensuing meta-
bolic processes to occur rapidly, and resulting image gen-
eration to occur in 52min (Brindle et al., 2011).
Deuteration is one means of overcoming this challenge
and recently, hyperpolarized, deuterated [U-2H, U-13C] glu-
cose was used to image glycolysis in real time (Rodrigues
et al., 2014). Initial results suggest the technique allows the
sensitive study of lactate accumulation in murine cancer
models pre- and post-chemotherapy.
Such techniques, although relatively early in develop-
ment, have clear application in mitochondrial disease, po-
tentially providing a minimally invasive, yet quantitative,
means of diagnosis—as well as a way of monitoring the
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systemic, or indeed tissue-specific, impact of a given treat-
ment. DNP is under active development in cancer medicine
and requires further validation in man before preliminary
assessments are made in mitochondrial disease specifically.
Preclinical work is also underway using novel PET lig-
ands, for example 18F-BCPP-EF, to enable quantitative
analysis of complex I activity. To date the technique has
been used following induced ischaemia in monkey brain
(Tsukada, 2014; Tsukada et al., 2014) and its application
to primary dysfunction of mitochondria has not been es-
tablished. However, the use of ligands with the ability to
interrogate specific mitochondrial complexes may in future
enable the non-invasive assessment of respiratory chain
function.
Emerging techniques
Small molecule reporters
Small molecule reporters enable the quantifiable measure-
ment of mitochondrial function, mitochondrial-specific me-
tabolites and reactive oxygen species generation in vivo.
Tailor-made probes, administered intravenously to an
intact organism, accumulate within mitochondria and
react with a substrate of interest. In doing so, the probes
are modified to produce an ‘exomarker’ (exogenous
marker), which can then be extracted to enable its quanti-
tative analysis, and inferences to be made about the react-
ing substrate. Currently, the technique is in preclinical
development, with analysis of the exomarker using mass
spectrometry only being feasible following destruction of
the organism (Logan et al., 2014). However, it is antici-
pated that further study of exomarkers in urine may facili-
tate analysis of probes in vivo and facilitate future work in
animal models and eventually, humans.
Although current focus of this technique is in the assess-
ment of acquired mitochondrial dysfunction arising due to
ischaemic and reperfusion insults (Chouchani et al., 2014),
the potential application to primary respiratory chain dis-
orders is evident. Such techniques would provide an attract-
ive way of ensuring drug delivery to mitochondria and
quantifying drug activity (Porteous et al., 2010;
Hoogewijs et al., 2016); as well as hypothetically determin-
ing optimal drug dosing for individual patients, or facilitat-
ing the direct assessment of mitochondrial function in
relation to disease progression.
Cutaneous respirometry
The ability to objectively measure respiratory chain func-
tion in vivo, non-invasively, and without need for imaging,
has the potential to revolutionize the follow-up and treat-
ment of those with mitochondrial disorders. Cutaneous
respirometry has been developed by a Dutch research
team investigating mitochondrial dysfunction arising due
to sepsis (Harms et al., 2015). The device, which sits
over the sternum, can measure both mitochondrial
oxygen tension (mitoPO2) and oxygen consumption
(mitoVO2). It does this by using the oxygen dependent op-
tical properties of protoporphyrin-IX, a haem precursor
synthesized within mitochondria, known as the PpIX-triplet
state lifetime technique. Testing in healthy volunteers is at
an early stage, but has confirmed that mitoPO2 and
mitoVO2 measurements are viable (Harms et al., 2016).
Furthermore, aside from minor local skin reactions, the
device was well tolerated. The application to mitochondrial
patients is evident and would be particularly suitable, fol-
lowing further assessment of reliability and validity, in the
setting of a natural history study, clinical trial or even rou-
tine clinic appointment.
Discussion
While mitochondrial disorders unite on a final common
metabolic pathway, their heterogeneous, multi-systemic
and fluctuating nature provides particular challenges in
the identification of biomarkers correlating with overall dis-
ease progression. Functional imaging studies and exercise
physiology are well established for the diagnosis of mito-
chondrial disorders, and both converge on impaired tissue
oxygen extraction. However, their role in measuring dis-
ease progression is less clear, and much could be gained
through well designed longitudinal studies of genotyped
cohorts using these modalities. The combination of bio-en-
ergetic and structural imaging is particularly promising,
particularly in evaluating mitochondrial cardiomyopathy
(Ng et al., 2016), but, the need for specialist equipment
and personnel conceivably limits their use. In contrast, cir-
culating serum markers, such as FGF-21 and GDF-15;
microRNA analysis and metabolomic assessment are ap-
pealing because the samples are relatively easy to collect
in both paediatric and adult mitochondrial populations.
However, it is currently not clear whether any serum or
blood-based biomarkers will be useful as endpoints in clin-
ical efficacy trials, particularly in groups that are genetically
and clinically heterogeneous, or where a tissue-specific
phenotype of interest falls within a multi-system mitochon-
drial disease syndrome. Longitudinal studies in patient co-
horts are required to clarify whether these approaches will
have a role in the future, or whether the integration of
different datasets using multivariate statistical methods,
for example, may help identify collections of markers that
together better reflect the complex nature of disease pro-
gression. Furthermore, as ‘signatures’ reflecting carrier
status have already been identified (Weiduschat et al.,
2014; Hall et al., 2015), the field needs to consider whether
inclusion of asymptomatic carrier individuals in observa-
tional and/or interventional studies should be facilitated.
Patients and their families want the least burdensome and
clear means to monitor progression of their disease so that
clinicians can provide timely and appropriate support.
Clinicians and industry partners urgently need new
2536 | BRAIN 2017: 140; 2530–2540 H. E. Steele et al.
biomarkers to facilitate clinical development of promising
novel treatments. How best to reach these goals and cap-
italize on the advances in biomarker techniques discussed is
a critical issue that needs to be collectively addressed by
clinicians, scientists, industry partners and patients, to
ensure a strategic, integrated and acceptable approach is
taken.
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